Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Abhijeet Bhardwaj's commitment to technical excellence and innovation continues to drive successful outcomes in large-scale ...

BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of ...

Becton, Dickinson and Co. (BD) is investing in its U.S. manufacturing network to add capacity for critical medical devices, ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Masimo: Szyman, who currently serves as president of Becton's patient monitoring unit, joined after the company last year ...